Rhabdomyosarcoma News and Research

RSS

Bedford Laboratories launches Dactinomycin for Injection

Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Dactinomycin for Injection USP 500 mcg (0.5 mg) to its comprehensive line of generic oncology products. Dactinomycin was approved earlier this year by the U.S. Food and Drug Administration (FDA) and is AP rated and equivalent to Cosmegen® by Lundbeck Inc. Each single dose vial contains 0.5 mg (500mcg) of dactinomycin and 20 mg of mannitol and is individually boxed.

12 Jul 2010

Scientists shrink distant sarcomas with genetically reprogrammed herpes virus and anti-vascular drug

Scientists have used a genetically reprogrammed herpes virus and an anti-vascular drug to shrink spreading distant sarcomas designed to model metastatic disease in mice – still an elusive goal when treating humans with cancer, according to a study in the July 8 Gene Therapy.

8 Jul 2010

Scientists use genetically reprogrammed herpes virus to shrink distant sarcomas

Scientists have used a genetically reprogrammed herpes virus and an anti-vascular drug to shrink spreading distant sarcomas designed to model metastatic disease in mice - still an elusive goal when treating humans with cancer, according to a study in the July 8 Gene Therapy.

8 Jul 2010

Cancer Research UK announces launch of new team to co-ordinate children's cancer trials

Birmingham will be at the forefront of developments in childhood cancer research thanks to the launch of a new team which will co-ordinate groundbreaking clinical trials across the UK.

16 Apr 2010

Fewer injections to treat neutropenia in childhood cancer patients

For patients like 10-year-old Sabrina Jo Spence, new research led by St. Jude Children's Research Hospital investigators meant fewer injections to combat the drop in white blood cells following her recent chemotherapy.

11 Mar 2010

Two young cancer patients receive grants from ProCure Cancer Foundation

Two young cancer patients from Virginia are the first recipients of grants from the ProCure Cancer Foundation, a new charitable organization that is providing financial assistance to families who cannot afford the nonmedical expenses associated with proton therapy.

3 Feb 2010

Zebrafish publishes special issue on cancer biology

The zebrafish, a translucent fish often used as a model of human development and disease, offers unique advantages for studying the cause, growth, and spread of tumors using strategies and methods presented in the current "Cancer Biology" special issue of Zebrafish, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). The entire issue is available free online at www.liebertpub.com/zeb

8 Jan 2010

Initiation of Phase I/IIa clinical trial of IL-7 announced

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of a Phase I/IIa clinical trial of IL-7 in support of tumor lysate/KLH pulsed dendritic cell vaccines in a pilot study of tumor vaccination in patients with metastatic or recurrent pediatric solid tumors and altered T cell homeostasis, including patients with Ewing’s sarcoma family of tumors (ESFT), rhabdomyosarcoma, neuroblastoma, synovial cell sarcoma, desmoplastic small round cell tumor, undifferentiated sarcoma, and embryonal sarcoma.

23 Nov 2009

Study links MiR-29 molecule to muscle maturation, muscle cancer

Researchers at The Ohio State University Comprehensive Cancer Center have discovered that a molecule implicated in leukemia and lung cancer is also important in muscle repair and in a muscle cancer that strikes mainly children.

1 Jan 2009

Immunotherapy shows promise in high-risk pediatric sarcomas

Based on a pilot study in children with sarcoma, researchers at the National Institutes of Health (NIH) believe that immunotherapy could prove beneficial in treating high-risk forms of this cancer.

3 Aug 2008

New advance in use of oncolytic viruses as novel cancer treatments

Combining a herpes virus genetically altered to express a drug-enhancing enzyme with a chemotherapy drug effectively and safely reduced the size of highly malignant human sarcoma grafted into mice.

22 Apr 2008

Novel anti-tumor compound

Researchers at Emory University have developed a novel anti-tumor compound that represents a distinct strategy: targeting one of the most important "intercept points" for cancer cells.

4 Jan 2008

New anti-cancer drug made from corn lillies kills brain tumor stem cells

A drug that shuts down a critical cell-signaling pathway in the most common and aggressive type of adult brain cancer successfully kills cancer stem cells thought to fuel tumor growth and help cancers evade drug and radiation therapy, a Johns Hopkins study shows.

30 Aug 2007

Rapamycin study is first stage in development of new treatment

Rapamycin isn't your ordinary potential anti-cancer drug…It had a long and somewhat exotic history before undergoing preclinical (laboratory-based) studies at St. Jude as part of a national Pediatric Preclinical Testing Program (PPTP) investigation of its anticancer activity.

23 Aug 2007

Researchers identify the cancer stem cell for rhabdomyosarcoma

As published in the June 1 issue of Genes & Development, Dr. Leonard Zon (Children's Hospital Boston) and colleagues have identified the cancer stem cell for rhabdomyosarcoma, the most common soft-tissue sarcoma of childhood.

17 May 2007

Childhood sarcoma increases risk of blood clots

Researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, have determined that children and young adults with a form of cancer called sarcoma are at increased risk of having a thromboembolic event (TE) in their veins.

20 Apr 2007

Mature muscle fibers can revert to become cancerous

Mature muscle fibers, rather than their less-developed neighbors, are the tissues that turn malignant in a soft-tissue cancer that strikes children and teens, researchers at UT Southwestern Medical Center and Children's Medical Center Dallas have found.

4 Sep 2006

Suppression of FOXO1a gene might kill resistant alveolar rhabdomyosarcoma (ARMS) tumors

FOXO1a caused death of tumor cells in laboratory study by triggering expression of caspase-3, which blocks cell division and causes cells to undergo apoptosis, according to St. Jude.

20 Sep 2005

Children treated for soft tissue sarcomas at greater risk of second cancers

A new study has found that although children treated for soft tissue sarcomas are surviving longer than they did in the past, they have an increased risk for second cancers, especially when initial treatment combined radiation and chemotherapy. This is according to analysis of data from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute.

27 Apr 2005

High risk of second cancers in survivors of childhood soft tissue sarcomas

Children treated for soft tissue sarcomas have a significantly higher risk of developing subsequent cancers later in life, according to a new study. The study appears in the June 1, 2005 issue of CANCER, a peer-reviewed journal of the American Cancer Society, and indicates children treated with combined chemotherapy and radiation therapy, in particular, had greater risks of developing a new malignancy.

25 Apr 2005